Reviewing Unum Therapeutics Inc. (UMRX)’s and La Jolla Pharmaceutical Company (NASDAQ:LJPC)’s results

Unum Therapeutics Inc. (NASDAQ:UMRX) and La Jolla Pharmaceutical Company (NASDAQ:LJPC) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Unum Therapeutics Inc. 8.05M 16.13 32.65M -1.54 0.00
La Jolla Pharmaceutical Company 5.87M 27.12 192.60M -7.91 0.00

Table 1 demonstrates Unum Therapeutics Inc. and La Jolla Pharmaceutical Company’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 provides us the return on assets, return on equity and net margins of both companies.

Net Margins Return on Equity Return on Assets
Unum Therapeutics Inc. -405.59% -383.1% -45%
La Jolla Pharmaceutical Company -3,281.09% -188% -94.3%

Liquidity

Unum Therapeutics Inc.’s Current Ratio and Quick Ratio are 3.4 and 3.4 respectively. The Current Ratio and Quick Ratio of its competitor La Jolla Pharmaceutical Company are 8.9 and 8.9 respectively. La Jolla Pharmaceutical Company therefore has a better chance of paying off short and long-term obligations compared to Unum Therapeutics Inc.

Analyst Recommendations

The next table highlights the delivered recommendations and ratings for Unum Therapeutics Inc. and La Jolla Pharmaceutical Company.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Unum Therapeutics Inc. 0 0 0 0.00
La Jolla Pharmaceutical Company 0 2 0 2.00

La Jolla Pharmaceutical Company on the other hand boasts of a $7.5 average price target and a 23.56% potential upside.

Insider and Institutional Ownership

The shares of both Unum Therapeutics Inc. and La Jolla Pharmaceutical Company are owned by institutional investors at 51.3% and 0% respectively. Insiders owned 33.98% of Unum Therapeutics Inc. shares. Insiders Comparatively, owned 5.2% of La Jolla Pharmaceutical Company shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Unum Therapeutics Inc. -19.13% -27.15% -54.22% -57.01% 0% -49.77%
La Jolla Pharmaceutical Company -4.56% -14.65% -38.27% -55.02% -56.94% -57.09%

For the past year Unum Therapeutics Inc.’s stock price has smaller decline than La Jolla Pharmaceutical Company.

Summary

On 7 of the 11 factors Unum Therapeutics Inc. beats La Jolla Pharmaceutical Company.

Unum Therapeutics Inc., a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma. The company's product portfolio also includes ACTR707 used in combination with rituximab that is in Phase I clinical trials to treat adult patients with r/r B cell non-Hodgkin lymphoma; ACTR087 used in combination with SEA-BCMA, which is in Phase I clinical trials for treating patients with r/r multiple myeloma; and ACTR707 used in combination with trastuzumab, which is in late preclinical development phase for treating HER2+ solid tumor cancers. It has strategic collaboration with Seattle Genetics, Inc. to identify, research, develop, and commercialize antibody-coupled T cell receptor therapies. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. It engages in developing LJPC-501, a formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension; and LJPC-401, a formulation of synthetic human hepcidin for the treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease, and myelodysplastic syndrome. The company is also developing LJPC-30S, which is the gentamicin derivative program for the potential treatment of serious bacterial infections and rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy. La Jolla Pharmaceutical Company was founded in 1989 and is headquartered in San Diego, California.